Bryn Pharma, LLC (“Bryn” or the “Company”), today announced that it has entered into an agreement with Aptar Pharma (AptarGroup NYSE: ATR), a leading drug delivery systems provider, for the supply and worldwide exclusive right to use Aptar’s novel, FDA-approved Bidose (BDS) nasal device for the delivery of epinephrine to treat anaphylaxis.
October 21, 2019
· 5 min read